Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, it researches, develops, manufactures, and markets medicines for serious chronic diseases. The company is listed on Nasdaq Copenhagen, with American Depositary Receipts traded in the U.S.
Core areas include diabetes and obesity, as well as rare endocrine and blood disorders. Its portfolio spans human and analogue insulins, GLP-1–based therapies, and other peptide and protein biologics. Novo Nordisk operates extensive bioprocessing, active pharmaceutical ingredient production, formulation, and fill–finish facilities worldwide, and collaborates with academic and industry partners on emerging modalities such as cell therapy.
